CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Three studies have reported expression signatures of CD34+ cells in relation to CML blast crisis and duration of chronic phase in patients treated with nonimatinib or imatinib therapy, respectively [35], [36], [37].